Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Corporate Update (February 2016)

26 slides from Sucampo Pharmaceuticals's corporate update, Feb 11, 2016

  1. Slide 1: Corporate Update

    $ SUCAMPO ‘The Science of Innovation Sucampo Pharmaceuticals, Inc. Corporate Update February 11, 2016 Peter Greenleaf, Chairman and Chief Executive Officer Silvia Taylor, Senior Vice President,

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements $ sucAMPO_ Reform Act of 1995. product potential It i The foll fact information, fut It th tionary statement March 9, 2015 as well filing of the Form 10-K,

  3. Slide 3: Investment Highlights

    Investment Highlights ¢$ sucAMPO @é@ iter etn prop! y drug vth fi (lubip: ): highly partnering: ophthalmic, i fi and oncology dineigers Cobipr signifi NERD/sGERD; Top-line data 1H1 6 VAP-1 inhibitor compounds for NASH, COPD Assets for out-licensing to create value

  4. Slide 4: Clear Strategy to Methodically Build a Leading Bio/Pharma Company

    Clear Strategy to Methodically Build a Leading Bio/Pharma e Company Revenue & Market Value Focus efforts and $ sucampo Transform capabilities = Development capability e = Efforts to ensure consistent and sustainable ae = Global p: - Sea eee with first filer Optimize investment in current pipeline =.

  5. Slide 5: AMITIZA: Constipation Market Overview

    AMITIZA: Constipation Market Overview $ SUCAMPO | lly (2015 annually (2015) US ‘nti d OT ket ~$5.2B ing 69 - $4.4B branded + generic market, ~50M annual scripts‘) * Majority of prescripti k 2.2 > eee" amitiza lubiprostone 1) Source: tS and Wall Sweet esearch 5

  6. Slide 6: Prescription Constipation Market Is Large and Growing

    Prescription Constipation Market Is Large and Growing $ SUCAMPO_ of Prescripti har ote n Products Chronic ° Idiopathic over 12 non-consecutive weeks within a Constipation 12-month period (cic) + ~14% to 16% of adults globally ‘Generic eer Irritable Bowel severe cramping, pain, bloating and Syndrome

  7. Slide 7: AMITIZA: Broadest Label in Constipation Market

    AMITIZA: Broadest Label in Constipation Market $ sucaMPo_ nly cic - IBS-C = OIC (non-cancer) — Increases intestinal fluid secretion « Key product characteristics Locally-acting Rapid and predictable onset of action + No black box warning * More than 90% of li i channels

  8. Slide 8: AMITIZA Prescription Growth is Accelerating

    AMITIZA Prescription Growth is Accelerating $ sucaMPo_ December Rx YOY growth rates: TRx 10%; NRx 14% U.S. TRx Scripts Japan TRx Scripts ‘analzed ‘Aaruslzes 3208 32048 (Thousands) (Thousands) 1345 ose 1118 tz (105 1231 ee 42641 L : 2008 2007 2008 2009 2010 2011 2012 2013 2014 _LTM_2015E 2012 2013 Li

  9. Slide 9: Blue-Chip Partnerships Provide Global Reach for AMITIZA

    Blue-Chip Partnerships Provide Global Reach for AMITIZA $ SUCAMPO Canada, U.K. Key Partnershi (Mylan) and China ; {Mylan for new formulations/indications US., Canada, Europe Japan 021 samuel Siiteeonens + Agreement with wlan for Japan Harbin Gloria Pharmaceuticals Co., Ltd. Mylan reimb Harbin Gloria

  10. Slide 10: Competitive Overview

    Competitive Overview $ sucampo_ AMITIZA i: itie Rxor orc Commentary Vamitiza mx Sem ey VOY VO tts rth net ay ta I 1 lubiprostone anes: “paueicensh| Altman + No limitation on durat So > Bisck box veering Son ahr aa Linzess* pq, ltonwood v v - ayy” Ofen used for the most severe patents Aecelepses (Mar

  11. Slide 11: AMITIZA Lifecycle Management

    AMITIZA Lifecycle Management $ SUCAMPO_ New Formulation or naso- gastric tube fed patients + Next step: Phase 3, commence 2H16 + U.S. Prevalence: 18% of pediatric population (13.5M) inp TC drugs off-label iP * Phase 3 program: - ulation: Children 6-17 year * Trial ongoing; Data 2H16 = lation: * Tria

  12. Slide 12: AMITIZA Growth Strategy

    AMITIZA Growth Strategy $ sucamPo_ o a GEOGRAPHY LABEL EXPANSION New Formulation 017) (2 Y Takeda —global + Expands market partnership ces ¥ Yearly I oo Se ncreeee) * Canad: Y Broad pediatric U, (new reco’s ;opulation Y¥ Gross-to-net cap “forapprovad coenaing y, for Sucampo: ROW infants to teens Und

  13. Slide 13: The Recent Addition of R-Tech Ueno Provides Significant Benefit

    The Recent Addition of R-Tech Ueno Provides Significant 4 SUCAMPO enefit “_— + Global pha Company Description Immediately and significantly . pr Coie onescaan + Strong and stable free cash flow cing profitability and free cash flow Takeda) Increased manufacturing and [J supply chain control existing

  14. Slide 14: Strengthened Financial Position of Combined Company

    Strengthened Financial Position of Combined Company $ sucampo_ Key Products Areas Number of Marketed Products LTM 6/30/15 Revenue LTM 6/30/15 Adjusted EBITDA Revenue by Product Revenue by Partner () Netotintercompanyeiinatens. (2) Inches $144 of cot synergies. $133.6M 59.1M RESCULA. ‘and Other re ot

  15. Slide 15: Product Pipeline Overview

    Product Pipeline Overview $ sucampo ‘Ophthalmology uot Rus05 RTU-1096 uFoa ‘Oncology Cobiprostone atc: TU096 Vert RK023 > receptor RTv-009 oe Sucampo Program Pediatric funcional eon 3 7016 2017 Cent copaue femultn edit funcional constipation; aduit a Re A NEROMGERD m2 8 200 Font! ASenonatus Pays Ps

  16. Slide 16: CPP-1X/sulindac Combo: Exclusive Option for Phase 3 Asset

    CPP-1X/sulindac Combo: in FAP * Significant opportunity Exclusive Option for Phase 3 Asset K ce No approved treatment options - a pation nee 00% risk of colon cancer room removal of colon/rectum ¢ uality of life - Incremental opportunity of $200M-S400M * De-risked sporadic colon adenoma/FAP — Define

  17. Slide 17: Cobiprostone: Phase 2 Asset in NERD/sGERD

    Cobiprostone: Phase 2 Asset in NERD/sGERD * Significant opportunity — 2-129 i roton-Pump Inhibitor NERI (PF Symptom (sGERD) patients refractory to PPIs relief only — Incremental opportunity of $500M-$1B s Differentiated | tight junctions in the epithelium membrane barrier function * Clinical develop

  18. Slide 18: R-Tech Ueno Pipeline

    R-Tech Ueno Pipeline VAP-1 inhibitors VAP-1 is an enzyme and adhesion receptor * RTU-1096 — MAD Phase 1b * RTU-009 - IV: acute inflammatory disease - Oral: . iti p t future extension Opportunity to be best-in-class

  19. Slide 19: Strong Financial Performance

    Strong Financial Performance $ sucampo_ Sucampo’s Strong Revenue Growth: @3 Sucampo is Profitable and Cash Generating: Q3 2M + Total revenues up 6% to $33.4M + Product royalty revenue up 15% to $19.3M > EPS = $0.16 milestone payment) Full Year Financial Guidance + Adjusted net income $80 S8N. - Incl

  20. Slide 20: Upcoming Milestones

    Upcoming Milestones $ SUCAMPO_ é Expected a ee ee Cobiprostone VAP-1 (RTU-1096), AMITIZA (lubiprostone) AMITIZA (lubiprostone) AMITIZA (lubiprostone) AMITIZA (lubiprostone) AMITIZA (lubiprostone) CPP-1X/sulindac. combination product Cobiprostone AMITIZA. (lubiprostone) p- 1H16 Top-line data from Pha

  21. Slide 21: Investment Highlights

    Investment Highlights ¢$ sucAMPO @é@ iter etn prop! y drug vth fi (lubip: ): highly partnering: ophthalmic, i fi and oncology dineigers Cobipr signifi NERD/sGERD; Top-line data 1H1 6 VAP-1 inhibitor compounds for NASH, COPD Assets for out-licensing to create value

  22. Slide 22: Back Up Slides

    Back Up Slides

  23. Slide 23: Patent Overview

    Patent Overview $ sucampo_ AIVITIZA * patent: J p through 2027 U.S. ‘067, '174, ‘649, U.S. ‘934 ‘890, ‘542, ‘393, ‘187, Patent expires 2021 ‘639 Latest patent expires 2027 ‘Composition of Matter Composition of Matter (Substance / AP!) (Product) AMITIZA Therapeutic use Manufacturing U.S. 182, '748, ‘

  24. Slide 24: Cobiprostone: Oral Mucositis

    Cobiprostone: Oral Mucositis * Significant opportunity = ~60KU i - ~550K therapies in the U.S. * Differentiated * Clinical development FDA fast-track designation — Phase 2 initiation 2H15 function 3-5% of all cancers are HNC a

  25. Slide 25: Proven and Experienced Management Team

    Proven and Experienced Management Team $ sucampo_ Peter Gi leaf °, aeesmtae Caeser sores [Ml fnenfptin Med Bristol Myers Squibb Ii Meine Peter Lichtlen, M.D., Ph.D. Chit Meieal Oc Alcon micr@met & novantis Il : ‘Medimmune Vivus a - Il Baxter Ss & werck ‘Medimmune SANOFI Stanley Miele Abbot iagnostio

  26. Slide 26: Sucampo Evolution

    Sucampo Evolution $ sucampo 1989 1994 1996 R-Tech Ueno, Ltd RESCULA |r. Sachiko Kuno and Dr. Ueno established launched in |found RTU Ueno (USA), inc. later to Japan eecome Sucampo 2006 62007 62008 2009 2010 2012. 013, 2014 2015 AMITIZA Initial Public AMITIZA — AMITIZA —- Sucampo MITIZA Named ‘Austri

Sucampo Pharmaceuticals — Corporate Update (February 2016) on 6ix